NCT00498927View on ClinicalTrials.gov

Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

temozolomide

GENETIC

protein expression analysis

GENETIC

reverse transcriptase-polymerase chain reaction

OTHER

diagnostic laboratory biomarker analysis

OTHER

immunoenzyme technique

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

Sponsors

Collaborators (1)

Schering-Plough
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Weill Medical College of Cornell University

OTHER

collaborator

Schering-Plough

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER